Advanomics Corporation to acquire Garmen Laboratories

Published: 27-Aug-2013

Garmen will manufacture 1kg of Adva-27a anticancer drug candidate for Sunshine Biopharma


Advanomics Corporation, a subsidiary of Sunshine Biopharma, a Canadian pharmaceutical company focused on the development of cancer drugs for the treatment of various forms of cancer, is to acquire GMP laboratory Garmen Laboratories for an undisclosed sum.

Garmen, a privately held Canadian firm located in Montreal, employs 45 people and provides pharmaceutical manufacturing and testing services to a broad range of industrial, institutional and governmental agencies. With nearly 35 years of industry experience, the firm offers solutions to detect, identify and quantify trace-level chemical components in the nutraceutical, food and pharmaceutical industries.

Garmen will also manufacture 1kg of Adva-27a, Sunshine Biopharma's flagship anticancer drug candidate in development for multidrug resistant cancers at its good manufacturing practices (GMP) lab in Montreal.

Advanomics said the material will be used to complete the remaining studies required to file an Investigational New Drug Application with the US FDA and conduct the breast cancer Phase I clinical trial of Adva-27a at McGill University's Jewish General Hospital in Montreal.

The firm recently received $1.45m in research grants from the NSERC, NanoQuebec and Canadian Institutes of Health Research (CIHR), to advance the development of Adva-27a.

'We are extremely pleased with the acquisition of Garmen Laboratories as it puts us in a prime position to continue to advance our novel cancer drug,' said Steve Slilaty, CEO of Sunshine Biopharma. 'We are excited that our methodical business plan in the development of Adva-27a is coming to fruition.'

You may also like